309 related articles for article (PubMed ID: 34347889)
1. 2021 update on clinical trials in β-thalassemia.
Musallam KM; Bou-Fakhredin R; Cappellini MD; Taher AT
Am J Hematol; 2021 Nov; 96(11):1518-1531. PubMed ID: 34347889
[TBL] [Abstract][Full Text] [Related]
2. New therapeutic targets in transfusion-dependent and -independent thalassemia.
Cappellini MD; Motta I
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):278-283. PubMed ID: 29222267
[TBL] [Abstract][Full Text] [Related]
3. Iron overload in thalassemia: different organs at different rates.
Taher AT; Saliba AN
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):265-271. PubMed ID: 29222265
[TBL] [Abstract][Full Text] [Related]
4. Unmet needs in β-thalassemia and the evolving treatment landscape.
Njeim R; Naouss B; Bou-Fakhredin R; Haddad A; Taher A
Transfus Clin Biol; 2024 Feb; 31(1):48-55. PubMed ID: 38128605
[TBL] [Abstract][Full Text] [Related]
5. How I treat non-transfusion-dependent β-thalassemia.
Saliba AN; Musallam KM; Taher AT
Blood; 2023 Sep; 142(11):949-960. PubMed ID: 37478396
[TBL] [Abstract][Full Text] [Related]
6. Management of transfusion-dependent β-thalassemia (TDT): Expert insights and practical overview from the Middle East.
El-Beshlawy A; Dewedar H; Hindawi S; Alkindi S; Tantawy AA; Yassin MA; Taher AT
Blood Rev; 2024 Jan; 63():101138. PubMed ID: 37867006
[TBL] [Abstract][Full Text] [Related]
7. α-Globin as a molecular target in the treatment of β-thalassemia.
Mettananda S; Gibbons RJ; Higgs DR
Blood; 2015 Jun; 125(24):3694-701. PubMed ID: 25869286
[TBL] [Abstract][Full Text] [Related]
8. Morbidities in non-transfusion-dependent thalassemia.
Saliba AN; Taher AT
Ann N Y Acad Sci; 2016 Mar; 1368(1):82-94. PubMed ID: 27186941
[TBL] [Abstract][Full Text] [Related]
9. Non-Transfusion-Dependent Thalassemia: An Update on Complications and Management.
Sleiman J; Tarhini A; Bou-Fakhredin R; Saliba AN; Cappellini MD; Taher AT
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29316681
[TBL] [Abstract][Full Text] [Related]
10. Thalassemia Intermedia: Chelator or Not?
Lee YC; Yen CT; Lee YL; Chen RJ
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077584
[TBL] [Abstract][Full Text] [Related]
11. Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation.
Motta I; Bou-Fakhredin R; Taher AT; Cappellini MD
Drugs; 2020 Jul; 80(11):1053-1063. PubMed ID: 32557398
[TBL] [Abstract][Full Text] [Related]
12. Transferrin receptor 2 (Tfr2) genetic deletion makes transfusion-independent a murine model of transfusion-dependent β-thalassemia.
Di Modica SM; Tanzi E; Olivari V; Lidonnici MR; Pettinato M; Pagani A; Tiboni F; Furiosi V; Silvestri L; Ferrari G; Rivella S; Nai A
Am J Hematol; 2022 Oct; 97(10):1324-1336. PubMed ID: 36071579
[TBL] [Abstract][Full Text] [Related]
13. Non-Transfusion-Dependent Thalassemia: A Panoramic Review.
Shash H
Medicina (Kaunas); 2022 Oct; 58(10):. PubMed ID: 36295656
[TBL] [Abstract][Full Text] [Related]
14. Liver iron concentrations and urinary hepcidin in beta-thalassemia.
Origa R; Galanello R; Ganz T; Giagu N; Maccioni L; Faa G; Nemeth E
Haematologica; 2007 May; 92(5):583-8. PubMed ID: 17488680
[TBL] [Abstract][Full Text] [Related]
15. β-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism.
Ginzburg Y; Rivella S
Blood; 2011 Oct; 118(16):4321-30. PubMed ID: 21768301
[TBL] [Abstract][Full Text] [Related]
16. Beta Thalassemia: Monitoring and New Treatment Approaches.
Khandros E; Kwiatkowski JL
Hematol Oncol Clin North Am; 2019 Jun; 33(3):339-353. PubMed ID: 31030806
[TBL] [Abstract][Full Text] [Related]
17. Beta-thalassemia and the advent of new interventions beyond transfusion and iron chelation.
Chauhan W; Shoaib S; Fatma R; Zaka-Ur-Rab Z; Afzal M
Br J Clin Pharmacol; 2022 Aug; 88(8):3610-3626. PubMed ID: 35373382
[TBL] [Abstract][Full Text] [Related]
18. β-Thalassemia: evolving treatment options beyond transfusion and iron chelation.
Langer AL; Esrick EB
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):600-606. PubMed ID: 34889443
[TBL] [Abstract][Full Text] [Related]
19. Pathophysiology of beta thalassemia--a guide to molecular therapies.
Thein SL
Hematology Am Soc Hematol Educ Program; 2005; ():31-7. PubMed ID: 16304356
[TBL] [Abstract][Full Text] [Related]
20. Preclinical transfusion-dependent humanized mouse model of beta thalassemia major.
Huo Y; McConnell SC; Ryan TM
Blood; 2009 May; 113(19):4763-70. PubMed ID: 19258591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
